
51 - 200 employees
🧬 Biotechnology
💊 Pharmaceuticals
Biotechnology • Pharmaceuticals
BBOT is a biotechnology company developing targeted therapies for cancers driven by RAS signaling and PI3Kα. The company focuses on rational drug design to inhibit the active ON state of RAS and to selectively block RAS-driven PI3K activation, aiming at multiple KRAS mutants and novel approaches to maximize target inhibition. BBOT translates decades of RAS biology research into therapeutic candidates intended to improve outcomes for patients with RAS- and PI3Kα-driven tumors.
🕒 July 3
Clinical Trial Manager overseeing execution of oncology clinical trials for BridgeBio Oncology Therapeutics. Focused on ensuring adherence to timelines, budgets, and quality standards.